Understanding how to improve immunity against CMV after bone marrow transplantation
Defining Protective CMV Immunity after Transplantation
['FUNDING_R01'] · FRED HUTCHINSON CANCER CENTER · NIH-11005717
This study is looking at how the immune system can help prevent Cytomegalovirus (CMV) from coming back in patients who have received a stem cell or bone marrow transplant, and it aims to find ways to boost that immunity to keep you healthier and reduce complications.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11005717 on ClinicalTrials.gov |
What this research studies
This research investigates the role of humoral immunity in preventing Cytomegalovirus (CMV) reactivation in patients who have undergone allogeneic hematopoietic stem cell or bone marrow transplantation. Using preclinical models, the study aims to explore how transferring immune T cells or specific antibodies can prevent CMV-related complications. The researchers will analyze the timing and mechanisms of CMV reactivation and the immune responses necessary for long-term control of the virus. Ultimately, the goal is to develop strategies to enhance CMV immunity while minimizing complications like graft-versus-host disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing allogeneic hematopoietic stem cell or bone marrow transplantation who are at risk for CMV reactivation.
Not a fit: Patients who are not undergoing transplantation or those who do not have a risk of CMV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing life-threatening CMV infections in transplant patients.
How similar studies have performed: Previous research has shown promising results in enhancing immunity against viral infections in transplant patients, suggesting that this approach could be effective.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HILL, GEOFFREY ROGER — FRED HUTCHINSON CANCER CENTER
- Study coordinator: HILL, GEOFFREY ROGER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.